Hugo Rupert Alexander Fry
Directeur Général chez Topas Therapeutics GmbH
Provenance du réseau au premier degré de Hugo Rupert Alexander Fry
Entité | Type d'entité | Industrie | |
---|---|---|---|
Topas Therapeutics GmbH
Topas Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Topas Therapeutics GmbH engages in pharmaceutical preparations. The company is headquartered in Hamburg, Germany.
6
| Holding Company | Pharmaceuticals: Major | 6 |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Acambis Research Ltd.
Acambis Research Ltd. Miscellaneous Commercial ServicesCommercial Services Acambis Research Ltd. was founded in 1992 and engages in research and experimental development on natural sciences and engineering. The joint venture company is based in Reading, UK.
1
| Joint Venture | Miscellaneous Commercial Services | 1 |
RPR (US) Ltd.
RPR (US) Ltd. Financial ConglomeratesFinance Part of Sanofi, RPR (US) Ltd. functions as an investment holding British company. The company is based in Guildford, UK.
1
| Subsidiary | Financial Conglomerates | 1 |
Aventis Pharma Ltd.
Aventis Pharma Ltd. Medical DistributorsDistribution Services Part of Sanofi, Aventis Pharma Ltd. is a British company that engages in the wholesale of pharmaceutical goods. The company is based in Reading, UK. Aventis Pharma was founded in 1980.
1
| Subsidiary | Medical Distributors | 1 |
Aventis Pharma Holdings Ltd.
Aventis Pharma Holdings Ltd. Financial ConglomeratesFinance Part of Sanofi, Aventis Pharma Holdings Ltd. functions as an investment holding British company. The company is based in Guildford, UK. Aventis Pharma Holdings was founded in 1999.
1
| Subsidiary | Financial Conglomerates | 1 |
Rhone-Poulenc Rorer Ltd.
Rhone-Poulenc Rorer Ltd. Pharmaceuticals: MajorHealth Technology Rhone-Poulenc Rorer Ltd. engages in the research, production and distribution of pharmaceutical products. The company is headquartered in Guildford, the United Kingdom.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Fisons Ltd.
Fisons Ltd. Pharmaceuticals: MajorHealth Technology Fisons Ltd. manufactures pharmaceutical preparations. The company is headquartered in Guildford, the United Kingdom.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Hoechst Marion Roussel Ltd. (United Kingdom)
Hoechst Marion Roussel Ltd. (United Kingdom) Pharmaceuticals: OtherHealth Technology Founded in 1994, Hoechst Marion Roussel Ltd. (United Kingdom) is a British pharmaceutical company that manufactures pharmaceutical products. Part of Sanofi, the company is based in Guildford, UK.
1
| Subsidiary | Pharmaceuticals: Other | 1 |
May & Baker Ltd.
May & Baker Ltd. Pharmaceuticals: MajorHealth Technology May & Baker Ltd. manufactures pharmaceutical products. The company is headquartered in Guildford, GB.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Hugo Rupert Alexander Fry via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Sanofi-Synthélabo Ltd.
Sanofi-Synthélabo Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Synthélabo Ltd. is a pharmaceutical company based in Reading, UK. The British company was founded in 1990 and specializes in manufacturing and distributing solid-dose and pharmaceutical products. | Pharmaceuticals: Major | Director/Board Member | |
SYNCONA LIMITED | Investment Trusts/Mutual Funds | Chief Executive Officer | |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member | |
BAXALTA INC | Biotechnology | Corporate Officer/Principal | |
NOVARTIS AG | Pharmaceuticals: Major | Director/Board Member | |
EVOTEC SE | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Leeds | College/University | Doctorate Degree | |
University of Copenhagen | College/University | Doctorate Degree | |
Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Private Equity Investor | |
Keystone Symposia
Keystone Symposia Miscellaneous Commercial ServicesCommercial Services Keystone Symposia operates as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops. The company was founded by C. Fred Fox in 1972 and is headquartered in Silverthorne, CO. | Miscellaneous Commercial Services | Director/Board Member | |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Harvard Medical School | College/University | Doctorate Degree | |
Sanofi-Synthelabo UK Ltd.
Sanofi-Synthelabo UK Ltd. Medical/Nursing ServicesHealth Services Sanofi-Synthelabo UK Ltd. provides healthcare solutions. The company was founded on May 16, 1961 and is headquartered in Guildford, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
Sanofi-Aventis UK Holdings Ltd.
Sanofi-Aventis UK Holdings Ltd. Financial ConglomeratesFinance Part of Sanofi, Sanofi-Aventis UK Holdings Ltd. functions as an investment holding company. The company is based in Guildford, UK and was founded in 1996. | Financial Conglomerates | Director/Board Member | |
H.I.G. BioVentures Advisors LLC | Corporate Officer/Principal | ||
Genzyme Ltd. (United Kingdom)
Genzyme Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Ltd. is a healthcare organization based in Haverhill, UK. Genzyme Ltd. is involved in research and development, transforming scientific innovation into healthcare solutions for people nationwide and across the globe. The British company witnesses the miracles of science when hard work results in new, cutting-edge medicines, services, and devices. Founded in 1981, the company works with the NHS and the pharmaceutical industry to deliver patient-centered initiatives, including joint working projects. | Pharmaceuticals: Major | Director/Board Member | |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Epidarex Capital Partners LLC
Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | Investment Managers | Private Equity Investor | |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
SYNTHORX, INC. | Biotechnology | Director/Board Member | |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Biotechnology | Director/Board Member | |
ARVINAS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
RUBIUS THERAPEUTICS | Biotechnology | Director/Board Member | |
KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
JOHNSON CONTROLS INTERNATIONAL PLC | Industrial Machinery | Director/Board Member | |
Clear Creek Bio, Inc.
Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Adorx Therapeutics Ltd.
Adorx Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adorx Therapeutics Ltd. provides biotechnology, health care and therapeutics services. The company is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
TOLREMO therapeutics AG
TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Epsilogen Ltd.
Epsilogen Ltd. Pharmaceuticals: MajorHealth Technology Epsilogen Ltd. engages in the development of immunoglobulin E (IgE) antibodies to treat cancer. The firm offers IGEG platform technology based on combining the power of IgE and Immunoglobulin G (IgG) antibody molecules. The company was founded by Sophia Karagiannis and James Spicer and is headquartered in London, United Kingdom. | Pharmaceuticals: Major | Chairman | |
ELIEM THERAPEUTICS, INC. | Biotechnology | Founder | |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Chief Executive Officer | |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
Curve Therapeutics Ltd.
Curve Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Lunac Therapeutics Ltd.
Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Leucid Bio Ltd.
Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Director/Board Member | |
Cellinta Ltd.
Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Investment Managers | Director/Board Member | |
HALEON PLC | Medical Distributors | Director/Board Member | |
Epidarex Exeed Ltd.
Epidarex Exeed Ltd. Miscellaneous Commercial ServicesCommercial Services Epidarex Exeed Ltd. is a British biotechnology company that specializes in research and experimental development. The company is based in Edinburgh, UK. The company was founded in 2019 by Elizabeth Ann Roper and Henning Steinhagen, with Henning Steinhagen serving as the CEO since its inception. | Miscellaneous Commercial Services | Director/Board Member | |
Lusaris Therapeutics, Inc.
Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Biotechnology | Chief Executive Officer | |
Superluminal Medicines Inc
Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Biotechnology | Director/Board Member | |
Sanofi Pasteur Holding Ltd.
Sanofi Pasteur Holding Ltd. Financial ConglomeratesFinance Part of Sanofi, Sanofi Pasteur Holding Ltd. functions as an investment holding British company. The company is based in Guildford, UK. | Financial Conglomerates | Director/Board Member | |
Clyde Biosciences Ltd.
Clyde Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Clyde Biosciences Ltd. provides developmental drug testing services. It offers drug screening, toxicity data analysis, direct measurements, and drug induced changes investigation services. Its services include calcium, voltage, contractility, in silico modeling, CiPA studies and bespoke R&D. The company was founded by Margaret Anne Craig, Godfrey Smith, Francis Burton, and Jon Cooper on March 9, 2012 and is headquartered in Glasgow, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member |
Statistiques
Internationale
Royaume-Uni | 23 |
Etats-Unis | 21 |
Danemark | 4 |
Allemagne | 4 |
Suisse | 3 |
Sectorielle
Health Technology | 26 |
Commercial Services | 10 |
Finance | 8 |
Consumer Services | 5 |
Miscellaneous | 2 |
Opérationnelle
Director/Board Member | 61 |
Corporate Officer/Principal | 13 |
Private Equity Investor | 9 |
Chief Executive Officer | 9 |
Independent Dir/Board Member | 8 |
Relations les plus connectées
Insiders | |
---|---|
Andrew Levin | 22 |
John Young | 17 |
Bram Vanparys | 14 |
Anne Prener | 14 |
Peter Finan | 14 |
Francois-Xavier Duhalde | 14 |
Stefan Herr | 4 |
Erich Greiner | 3 |
Christian Schröter | 2 |
James Januzzi | 1 |
Erich F. Greiner | 1 |
- Bourse
- Insiders
- Hugo Rupert Alexander Fry
- Connexions Sociétés